The experiments presented here demonstrate that thioridazine can reduce the number of OCT4-expressing cells within malignant teratocarcinomas and extend the survival of tumor-bearing mice, including a human EC xenograft model, and may therefore be a good alternative or adjunctive treatment for malignant TGCTs. Here, POU5F1 is linked to neoplasm.